drug_type
RELEVANT_DRUG
intervention_type
Drug (antibody-drug conjugate)
drug_description
An anti-HER2 antibody-drug conjugate composed of a humanized IgG1 anti-HER2 antibody (trastuzumab) linked via a cleavable linker to a membrane-permeable topoisomerase I inhibitor payload (DXd). It binds HER2/ERBB2 on tumor cells, mediates partial HER2 signaling blockade and ADCC, and after internalization releases DXd to inhibit topoisomerase I, causing DNA damage, apoptosis, and a bystander effect. Dosed at 5.4 mg/kg IV every 3 weeks.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
trastuzumab deruxtecan
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized anti‑HER2 (trastuzumab) antibody linked via a cleavable linker to a membrane‑permeable topoisomerase I inhibitor (DXd). Binds HER2 on tumor cells to enable internalization; linker cleavage releases DXd to inhibit topoisomerase I, causing DNA damage and apoptosis, with a bystander effect. The antibody component also partially blocks HER2 signaling and mediates Fc‑dependent ADCC.
drug_name
Trastuzumab deruxtecan (T-DXd)
nct_id_drug_ref
NCT05982678